Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy

• Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relapse and subsequent prolonged disease course...

Descripción completa

Detalles Bibliográficos
Autores principales: Furlan, Anna, Forner, Gabriella, Cipriani, Ludovica, Vian, Elisa, Rigoli, Roberto, Gherlinzoni, Filippo, Scotton, Piergiorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139434/
https://www.ncbi.nlm.nih.gov/pubmed/34217677
http://dx.doi.org/10.1016/j.clml.2021.05.013
_version_ 1783696006351683584
author Furlan, Anna
Forner, Gabriella
Cipriani, Ludovica
Vian, Elisa
Rigoli, Roberto
Gherlinzoni, Filippo
Scotton, Piergiorgio
author_facet Furlan, Anna
Forner, Gabriella
Cipriani, Ludovica
Vian, Elisa
Rigoli, Roberto
Gherlinzoni, Filippo
Scotton, Piergiorgio
author_sort Furlan, Anna
collection PubMed
description • Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relapse and subsequent prolonged disease course, with rapid and significant response to convalescent hyperimmune plasma in association with an extended course of remdesivir. The clinical observations here reported suggest that the immunological effects of Rituximab treatment in NHL patients should be taken into account for the proper choice and interpretation of SARS-CoV-2 laboratory tests and to guide the appropriate therapeutical approach.
format Online
Article
Text
id pubmed-8139434
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-81394342021-05-24 Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy Furlan, Anna Forner, Gabriella Cipriani, Ludovica Vian, Elisa Rigoli, Roberto Gherlinzoni, Filippo Scotton, Piergiorgio Clin Lymphoma Myeloma Leuk Case Report • Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relapse and subsequent prolonged disease course, with rapid and significant response to convalescent hyperimmune plasma in association with an extended course of remdesivir. The clinical observations here reported suggest that the immunological effects of Rituximab treatment in NHL patients should be taken into account for the proper choice and interpretation of SARS-CoV-2 laboratory tests and to guide the appropriate therapeutical approach. Elsevier Inc. 2021-09 2021-05-21 /pmc/articles/PMC8139434/ /pubmed/34217677 http://dx.doi.org/10.1016/j.clml.2021.05.013 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Furlan, Anna
Forner, Gabriella
Cipriani, Ludovica
Vian, Elisa
Rigoli, Roberto
Gherlinzoni, Filippo
Scotton, Piergiorgio
Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
title Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
title_full Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
title_fullStr Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
title_full_unstemmed Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
title_short Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell–Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy
title_sort dramatic response to convalescent hyperimmune plasma in association with an extended course of remdesivir in 4 b cell–depleted non-hodgkin lymphoma patients with sars-cov-2 pneumonia after rituximab therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139434/
https://www.ncbi.nlm.nih.gov/pubmed/34217677
http://dx.doi.org/10.1016/j.clml.2021.05.013
work_keys_str_mv AT furlananna dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy
AT fornergabriella dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy
AT ciprianiludovica dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy
AT vianelisa dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy
AT rigoliroberto dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy
AT gherlinzonifilippo dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy
AT scottonpiergiorgio dramaticresponsetoconvalescenthyperimmuneplasmainassociationwithanextendedcourseofremdesivirin4bcelldepletednonhodgkinlymphomapatientswithsarscov2pneumoniaafterrituximabtherapy

Ejemplares similares